anti-idiotype rna selected with an anti-nuclear export signal antibody is actively transported in oocytes and inhibits rev- and cap-dependent rna export.

NLM AIDSLINE Anti-idiotype RNA selected with an anti-nuclear export signal antibody is actively transported in oocytes and inhibits Rev- and cap-dependent RNA export. Hamm J; Huber J; Luhrmann R; Department of Biochemistry, University of
March 30, 1998

Proc Natl Acad Sci U S A. 1997 Nov 25;94(24):12839-44. Unique Identifier The anti-idiotype approach is based on the assumption that an antibody specific for a receptor-binding domain of a ligand could be structurally related to the receptor. Therefore, a structural mimic of a receptor-binding domain, selected with an anti-ligand antibody, might be a functional substrate for the receptor. This hypothesis was addressed here by generating antibodies recognizing the Rev-nuclear export signal (NES). A functional NES is required for active export, presumably by interacting directly or indirectly with the nuclear pore complex. Anti-NES antibodies were used to isolate RNA mimics of the NES peptide from combinatorial RNA libraries. The RNA-mimics are exported actively, block Rev-dependent export of a reporter RNA, and inhibit cap-dependent U1 snRNA export in Xenopus oocytes, properties previously reported for NES-peptide conjugates. Antibodies, Anti-Idiotypic/IMMUNOLOGY Cell Nucleus/METABOLISM Gene Products, rev/ANTAGONISTS & INHIB Gene Products, rev/METABOLISM Oocytes/METABOLISM RNA/METABOLISM *RNA Caps

Most Read: Latest Added Related Topics White House LGBT Conference on HIV/AIDS UNITED STATES: White House in Atlanta: LGBT AIDS Conference No more single-theme conferences: global HIV prevention conference planned FHI 360 Senior Scientist Lut Van Damme Receives International Microbicide Conference Lifetime Achievement Award Equatorial Guinea Ministry of Health and Social Welfare and UNICEF Refute Erroneous AIDS Prevalence Figures Photographs from A Day with HIV Now Online Bulgaria urges Libya to investigate AIDS nurses case Engineers enter fight against AIDS in Africa Gilead’s Complera® Non-Inferior to Atripla® Among Treatment-Naive HIV Patients UN chief Ban calls world leaders to end Aids by 2020 Positive living Lawyer: NY man at center of HIV scare not positive Zimbabwe activist: Prisoners denied AIDS drugs Youth organizations form a pact for social transformation in the AIDS response CountyCare Offers Historic Opportunity to Improve Care for People with HIV International AIDS Advocates Demand China Give $1 Billion to Global Fund Kingdom of Bahrain and UNAIDS commit to intensify cooperation CANADA: Celibate Homosexual Men Now Allowed to Donate Blood in Canada AFRICA: UN: AIDS Deaths Down, Treatment Up in Africa MICHIGAN: STD Fee for Jackson County Walk-In Clinic Takes Effect June 3 La lutte anti-sida de demain: pas de baguette magique mais un cocktail WALES: HIV Patients Are at Risk of Being Identified Because of New Prescribing System, Warns AM Russia has 'no anti-AIDS strategy': official NIH Scientists Create New Tool for Identifying Powerful HIV Antibodies: Advance Could Speed HIV Vaccine Research Feuding antibodies blocked HIV vaccine Challenge to overcome earlier anti-gay prejudices New Findings from A.M. Cavalcanti and Colleagues Has Provided New Data on Genetics and HIV/AIDS Free Speech and an Anti-Prostitution Pledge Anti-HIV therapy appears to protect children's hearts, NIH network study shows Antibody evolution could guide HIV vaccine development
Information in this article was accurate in March 30, 1998. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.